Team Science conducted the study that demonstrated the efficacy of one of the first vaccines against RSV in older adults. Currently, the administration of a second dose of the vaccine, two years after the initial one, is being evaluated in a group of the same volunteers who participated in that first stage. The objective of this new phase is to analyze the immunological response in previously vaccinated persons.
